Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.2.8935.9629
Address
Level 5 7 Eden Park Drive Macquarie Park, New South Wales (NSW) 2113
Description
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. It engages in the development of novel and safer radiation therapy treatments. The company was founded by David McAuliffe on April 14, 2005 and is headquartered in North Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.01
Trade Value (12mth)
AU$12,496.00
1 week
14.29%
1 month
0%
YTD
-42.86%
1 year
-11.11%
All time high
0.20
EPS 3 yr Growth
-44.30%
EBITDA Margin
%
Operating Cashflow
-$11m
Free Cash Flow Return
-147.50%
ROIC
-162.30%
Interest Coverage
-3,293.30
Quick Ratio
3.30
Shares on Issue (Fully Dilluted)
3975m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
07 May 25 |
OncoSil Outperforms SBRT in Pancreatic Cancer Outcomes
×
OncoSil Outperforms SBRT in Pancreatic Cancer Outcomes |
05 May 25 |
Application for quotation of securities - OSL
×
Application for quotation of securities - OSL |
02 May 25 |
Quarterly Activities/Appendix 4C Cash Flow Report Addendum
×
Quarterly Activities/Appendix 4C Cash Flow Report Addendum |
01 May 25 |
Consolidation/Split - OSL
×
Consolidation/Split - OSL |
01 May 25 |
Update - Consolidation/Split - OSL
×
Update - Consolidation/Split - OSL |
30 April 25 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
30 April 25 |
Tender Process for CRO to Undertake G-BA Study Commences
×
Tender Process for CRO to Undertake G-BA Study Commences |
29 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
01 April 25 |
Appointment of Company Secretary
×
Appointment of Company Secretary |
18 March 25 |
OncoSil appoints Ms Shelley Steyn as Chief Financial Officer
×
OncoSil appoints Ms Shelley Steyn as Chief Financial Officer |
25 February 25 |
Appendix 4D and Half Year Accounts
×
Appendix 4D and Half Year Accounts |
11 February 25 |
Investor Webinar Presentation
×
Investor Webinar Presentation |
07 February 25 |
Investor Webinar 11 February 2025
×
Investor Webinar 11 February 2025 |
04 February 25 |
120 German Hospitals entitled to negotiate fee for OncoSil
×
120 German Hospitals entitled to negotiate fee for OncoSil |
31 January 25 |
Response to Appendix 3X Query
×
Response to Appendix 3X Query |
30 January 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 January 25 |
Initial Director's Interest Notice LS
×
Initial Director's Interest Notice LS |
28 January 25 |
OncoSil Medical Receives MDR Approval
×
OncoSil Medical Receives MDR Approval |
15 January 25 |
Lel Smits to be appointed Non-Executive Director
×
Lel Smits to be appointed Non-Executive Director |
08 January 25 |
OncoSil receives $1.05m R&D tax incentive
×
OncoSil receives $1.05m R&D tax incentive |
31 December 24 |
First Patient in Australia Randomised in TRIPP-FFX Trial
×
First Patient in Australia Randomised in TRIPP-FFX Trial |
20 December 24 |
Change of Director's Interest Notice DC
×
Change of Director's Interest Notice DC |
13 December 24 |
Oncosil completes $1 million Share Purchase Plan (SPP)
×
Oncosil completes $1 million Share Purchase Plan (SPP) |
13 December 24 |
Application for quotation of securities - OSL
×
Application for quotation of securities - OSL |
13 December 24 |
Application for quotation of securities - OSL
×
Application for quotation of securities - OSL |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.